MARKET

MEIP

MEIP

Mei Pharma Inc
NASDAQ
6.72
-0.01
-0.15%
After Hours: 6.77 +0.05 +0.74% 18:44 12/08 EST
OPEN
6.82
PREV CLOSE
6.73
HIGH
6.88
LOW
6.56
VOLUME
35.00K
TURNOVER
0
52 WEEK HIGH
6.91
52 WEEK LOW
3.107
MARKET CAP
44.77M
P/E (TTM)
1.088
1D
5D
1M
3M
1Y
5Y
Mei Pharma Inc: Correspondence
Press release · 4d ago
Mei Pharma Inc: [Cover]SEC-generated letter
Press release · 4d ago
Weekly Report: what happened at MEIP last week (1127-1201)?
Weekly Report · 5d ago
Weekly Report: what happened at MEIP last week (1120-1124)?
Weekly Report · 11/27 09:53
Weekly Report: what happened at MEIP last week (1113-1117)?
Weekly Report · 11/20 09:53
12 Health Care Stocks Moving In Thursday's Intraday Session
Lumiradx shares rose 42.8% to $0.14 during thursday's regular session. The company's stock is trading at a volume of 62.6 million shares as of 12:30 est. Impel pharmaceuticals (nasdaq:impl) shares moved upwards by 25%. Bone biologics stock rose 26.55% during the session.
Benzinga · 11/16 17:31
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers bone biologics (nasdaq:bblg) stock increased by 64.3% to $0.89 during thursday's pre-market session. Invivo therapeutics hldg stock rose 24.66% after the company's q3 earnings came out. Heart test laboratories shares increased by 14.33% and biovie stock rose by 13.33%.
Benzinga · 11/16 13:06
Mei Pharma Inc: Initial statement of beneficial ownership of securities
Press release · 11/16 11:03
More
About MEIP
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).

Webull offers MEI Pharma Inc stock information, including NASDAQ: MEIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEIP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MEIP stock methods without spending real money on the virtual paper trading platform.